Matinas BioPharma Holdings (MTNB) Cash & Current Investments (2013 - 2026)

Matinas BioPharma Holdings (MTNB) has 14 years of Cash & Current Investments data on file, last reported at $2.4 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $2.4 million, down 64.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 million (down 64.9% YoY), and the FY2025 annual result was $4.0 million, down 44.79% from the prior year.
• Cash & Current Investments fell to $2.4 million in Q1 2026 per MTNB's latest filing, from $4.0 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $43.8 million in Q1 2022 and troughed at $1.1 million in Q1 2024.
• A 5-year average of $13.5 million and a median of $7.0 million in 2025 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments slumped 86.79% in 2023, then soared 522.12% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $6.9 million in 2022, then jumped by 99.94% to $13.8 million in 2023, then plunged by 46.69% to $7.3 million in 2024, then sank by 44.79% to $4.0 million in 2025, then slumped by 39.54% to $2.4 million in 2026.
• Business Quant data shows MTNB's Cash & Current Investments at $2.4 million in Q1 2026, $4.0 million in Q4 2025, and $5.5 million in Q3 2025.